Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, Multi-center, Phase I Clinical Study on the Safety and Efficacy of HGI-001 Injection in Patients with Transfusion-Dependent Β-Thalassemia.

NCT06655662 is registered in ClinicalTrials.gov with Shenzhen Hemogen as lead sponsor.

NCT NCT06655662
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06655662 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, Multi-center, Phase I Clinical Study on the Safety and Efficacy of HGI-001 Injection in Patients with Transfusion-Dependent Β-Thalassemia.
Lead sponsor
Shenzhen Hemogen
Phase
Phase 1
Overall status
Recruiting
Start date
June 12, 2024
Completion date
December 31, 2026
Enrollment
8 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

Β-thalassemia